Back to Browse Journals » Drug Design, Development and Therapy » Volume 4

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections

Authors Emily Zoller, Connie Valente, Kyle Baker, et al

Published Date November 2010 Volume 2010:4 Pages 299—311

DOI http://dx.doi.org/10.2147/DDDT.S7773

Published 4 November 2010

Emily Zoller, Connie Valente, Kyle Baker, Michael E Klepser
Ferris State University College of Pharmacy, Kalamazoo, Michigan, USA

Abstract: Posaconazole is an extended-spectrum azole antifungal that exhibits activity against a broad range of fungal pathogens, including yeasts and moulds. Clinical data have demonstrated the clinical utility of posaconazole against many therapy-refractory pathogens, including Aspergillus spp, Fusarium spp, and Zygomycetes. These data have provided clinicians with hope in these difficult situations. Some of the limitations that have emerged with the use of posaconazole are the lack of an intravenous formulation and erratic drug absorption. This fact is further complicated by the existence of saturable posaconazole absorption. Despite these drawbacks, posaconazole appears poised to become a prominent therapeutic modality for the prophylaxis and management of various fungal infections among high-risk patients.

Keywords: posaconazole, pharmacokinetics, fungal infections

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Moderate alcohol consumption and cognitive risk

Neafsey EJ, Collins MA

Neuropsychiatric Disease and Treatment 2011, 7:465-484

Published Date: 11 August 2011

Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB

Infection and Drug Resistance 2011, 4:97-113

Published Date: 3 May 2011

Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine

Duncan RS, Xin H, Goad DL, Chapman KD, Koulen P

Clinical Ophthalmology 2011, 5:543-548

Published Date: 26 April 2011

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

Mark A Giembycz, Stephen K Field

Drug Design, Development and Therapy 2010, 4:147-158

Published Date: 14 July 2010

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al

Drug Design, Development and Therapy 2010, 4:117-126

Published Date: 18 June 2010

Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections

Dionissios Neofytos, Edina Avdic, Anna-Pelagia Magiorakos

Drug, Healthcare and Patient Safety 2010, 2:27-38

Published Date: 20 April 2010

Review of the pharmacology and clinical studies of micafungin

Alison M Bormann, Vicki A Morrison

Drug Design, Development and Therapy 2009, 3:295-302

Published Date: 10 December 2009